Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of ofatumumab 20 mg SC via pre-filled syringe vs autoinjector in RMS
2017-004702-17Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ofatumumab in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Primary endpoints: AUC after Week 8 dose and Cmax after Week 8 dose. Started Aug 2018; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2017-004702-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004702-17.